A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
Latest Information Update: 19 Feb 2024
At a glance
- Drugs Nemolizumab (Primary)
- Indications Atopic dermatitis
- Focus Pharmacodynamics
- Sponsors Galderma Research & Development
- 15 Feb 2024 Status changed from active, no longer recruiting to completed.
- 22 Jan 2024 Planned End Date changed from 23 Oct 2023 to 15 Feb 2024.
- 21 Aug 2023 Planned End Date changed from 25 Sep 2023 to 23 Oct 2023.